Log in

OTCMKTS:OPHLYONO PHARMACEUTI/ADR Stock Price, Forecast & News

$9.54
+0.11 (+1.17 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$9.52
Now: $9.54
$9.76
50-Day Range
$8.30
MA: $9.24
$9.84
52-Week Range
$5.25
Now: $9.54
$10.00
Volume2,906 shs
Average Volume16,982 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Ono Pharmaceutical Co., Ltd. produces and sells pharmaceuticals and diagnostic reagents worldwide. Its products include OPDIVO intravenous infusions for the treatment of malignant tumor; KYPROLIS, a proteasome inhibitor for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; GLACTIV and FORXIGA tablets for type 2 diabetes; KINEDAK tablets to treat diabetic peripheral neuropathy; PARSABIV, an intravenous injection for dialysis patients; RECALBON tablets to treat osteoporosis; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; ONOACT injections for treating tachyarrhythmia; Staybla tablets for overactive bladder; OPALMON tablets to treat peripheral circulatory disorder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; and Foipan tablets to treat chronic pancreatitis and postoperative reflux esophagitis. The company is also developing products for malignant pleural mesothelioma, glioblastoma, multiple myeloma, solid tumors, chronic myeloid and acute leukemia, melanoma, pheochromocytoma, cancer anorexia/cachexia, ventricular arrhythmia, tachyarrhythmia, lupus nephritis, untreated rheumatoid arthritis, primary sjögren syndrome, polymyositis/dermatomyositis, chronic heart failure, osteoarthritis, parkinson's disease, enthesopathy, sepsis, hepatitis C, sjögren syndrome, autoimmune disease, and acromegaly; small cell lung, esophageal, gastric or esophago-gastric junction, ovarian, colorectal, pancreatic, prostate, biliary tract, hematologic, small and non-small cell lung, head and neck, and esophageal cancers; hepatocellular, urothelial, virus positive/negative solid, and renal cell carcinoma; and central nervous system, primary testicular, diffuse large B cell, follicular lymphoma, B cell, and non-Hodgkin lymphoma. It has a drug discovery research collaboration with twoXAR, Inc. The company was founded in 1717 and is headquartered in Osaka, Japan.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.46 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceuticals: Other
Sub-IndustryN/A
Current SymbolOTCMKTS:OPHLY
CUSIPN/A
CIKN/A
Phone(166) 263-5670

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees3,480
Next Earnings DateN/A
OptionableNot Optionable

Receive OPHLY News and Ratings via Email

Sign-up to receive the latest news and ratings for OPHLY and its competitors with MarketBeat's FREE daily newsletter.

ONO PHARMACEUTI/ADR (OTCMKTS:OPHLY) Frequently Asked Questions

How has ONO PHARMACEUTI/ADR's stock been impacted by COVID-19 (Coronavirus)?

ONO PHARMACEUTI/ADR's stock was trading at $6.45 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, OPHLY shares have increased by 47.8% and is now trading at $9.5350. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of ONO PHARMACEUTI/ADR?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ONO PHARMACEUTI/ADR in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ONO PHARMACEUTI/ADR.

Has ONO PHARMACEUTI/ADR been receiving favorable news coverage?

Media coverage about OPHLY stock has been trending negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ONO PHARMACEUTI/ADR earned a news impact score of -2.1 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news about ONO PHARMACEUTI/ADR.

Who are some of ONO PHARMACEUTI/ADR's key competitors?

Who are ONO PHARMACEUTI/ADR's key executives?

ONO PHARMACEUTI/ADR's management team includes the following people:
  • Mr. Gyo Sagara, CEO, Pres & Representative Director
  • Toichi Takino, Corp. Officer, Exec. Director of Discovery & Research
  • Yukio Tani, Corp. Exec. Officer & Director of Corp. Communications
  • Mr. Hiroshi Ichikawa, Corp. Exec. Officer and Exec. Director of Sales & Marketing
  • Mr. Kei Sano, Sr. Exec. Officer & Exec. Director of Gen. Admin. Headquarters and Director

What is ONO PHARMACEUTI/ADR's stock symbol?

ONO PHARMACEUTI/ADR trades on the OTCMKTS under the ticker symbol "OPHLY."

How do I buy shares of ONO PHARMACEUTI/ADR?

Shares of OPHLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ONO PHARMACEUTI/ADR's stock price today?

One share of OPHLY stock can currently be purchased for approximately $9.54.

What is ONO PHARMACEUTI/ADR's official website?

The official website for ONO PHARMACEUTI/ADR is www.ono.co.jp.

How can I contact ONO PHARMACEUTI/ADR?

The company can be reached via phone at (166) 263-5670.

This page was last updated on 7/6/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.